39560-33-3

Basic information

• Product Name: 6-(4-hydroxyphenyl)-4,5-dihydro-3(2H)-pyridazinone
• Synonyms: 6-(4-hydroxyphenyl)-4,5-dihydro-3(2H)-pyridazinone
• CAS NO: 39560-33-3
• Molecular Weight: 190.202
• Mol File: 39560-33-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 6-(4-hydroxyphenyl)-4,5-dihydro-3(2H)-pyridazinone(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4-hydroxyphenyl)-4,5-dihydro-3(2H)-pyridazinone(39560-33-3)
• EPA Substance Registry System: 6-(4-hydroxyphenyl)-4,5-dihydro-3(2H)-pyridazinone(39560-33-3)

Safety Data

• Hazardous Substances Data: 39560-33-3(Hazardous Substances Data)

Upstream product

• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 1010800-67-5 tert-butyl 4-(4-methoxyphenyl)-4-oxobutanoate 
• 1017-06-7 6-(4-Methoxyphenyl)-4,5-dihydro-2H-pyridazin-3-one 
• 3153-44-4 4-(4-methoxy-phenyl)-4-oxo-butyric acid 

Downstream Products

• 54851-73-9 6-(4-hydroxyphenyl)-3(2H)-pyridazinone 
• 1010801-81-6 C₂₈H₂₉F₃N₆O₄ 
• 504-30-3 2H-Pyridazin-3-one 
• 56872-16-3 6-(4-allyloxy-phenyl)-4,5-dihydro-2H-pyridazin-3-one 

Relevant articles and documents

Phosphodiesterase inhibitors. Part 5: Hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration

(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl) -5-methyl-4,5-dihydropyridazin-3(2H)-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory activity and promises as a combined bronchodilatory/anti- inflammatory agent. N-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition. Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent PDE3 inhibition. Both dihydropyridazinone rings, in the core and extension, can be replaced by achiral 4,4-dimethylpyrazolone subunits and the core pyrazolopyridine by isosteric bicyclic heteroaromatics. In combination, these modifications afford potent dual PDE3/4 inhibitors that suppress histamine-induced bronchoconstriction in vivo and exhibit promising anti-inflammatory activity via intratracheal administration.

PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyrazolone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1,R2: C1-6 alkyl; R3,R4: H, X, C1-6 alkoxy; Z:O, S; A:AA, BB, wherein AA represents wherein BB represents wherein R5: H, C1-6 alkyl ; R6,R7: C1-6 alkyl.

Pyridazinones

Compounds of the general formula: SPC1 In which X represents a straight or branched chain alkyl or alkoxy group, a hydroxymethyl group, a cycloalkyl group, a cycloalkoxy group, an aryloxy group, a hydroxyl group, a fluorine atom, a chlorine atom, an amino or substituted amino group, a piperidino group, a morpholino group, a pyrrolidino group, a 1,2,3,6-tetrahydropyridino group, a 4-[3-azabicyclo(3,2,2)-nonyl] group, or a 4-(piperazin-1-yl) or 4-(4-substituted-piperazin-1-yl) group of the formula SPC2 In which R=H, lower alkyl or 1-5 carbon atoms, aryl, substituted aryl, aralkyl, cinnamyl, acyl, ethoxy-carbonyl, aroyl or substituted aroyl and n is an integer from 1 to 5 except that when n is 1 X is not an alkyl group of 1 to 3 carbon atoms or an alkoxy group of 1 or 2 carbon atoms or a chlorine atom in the 4'-position, or an amino or acylated amino group in positions 2', 3' or 4'; and when n = 2 the groups X cannot both be methyl or both be methoxy in the 2' and 5' positions, nor can X be a chlorine atom in both the 2' and 4' positions or the 3' and 4' positions, and when n = 3, X cannot all three be methoxy. These compounds have anti-hypertensive activity.